Skip to content

Study · Not a test of the peptide alone · 2021

12 results

Effects of GLP-1 receptor agonists on myokine levels and pro-inflammatory cytokines in patients with type 2 diabetes mellitus.

Guarnotta V, Bianco MJ, Vigneri E, Panto' F, Lo Sasso B, Ciaccio M, Pizzolanti G, Giordano C

Nutrition, metabolism, and cardiovascular diseases : NMCD24 Jul 2021Cited by 29 (Europe PMC)

PMID34518091 (opens in a new tab)DOI10.1016/j.numecd.2021.07.015 (opens in a new tab)PepBankPUB-34518091
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone12

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes, pooled dulaglutide or liraglutide added to existing treatment significantly decreased BMI after 6 months.

    In plain wordsIn adults with type 2 diabetes, adding dulaglutide or liraglutide was linked to a lower BMI after 6 months.

    Peptide
    Liraglutide
    Outcome
    DecreaseBMI change after 6 months
    Study

    n = 85

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    After 6 months of GLP-1 analogues a significant decrease in BMI (p < 0.001), waist circumference (WC) (p < 0.001), fasting blood glucose (p < 0.001), HbA1c (p < 0.001), total cholesterol (p < 0.001), LDL-cholesterol (p = 0.003), triglycerides (p = 0.017), IL-6 (p = 0.045) and a significant increase…
    1 context sentence
    Summary · context
    Eighty-five patients with T2DM inadequately controlled with insulin or other hypoglycaemic drugs were added to dulaglutide (N° = 44) and liraglutide (N° = 41) treatment.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes, pooled dulaglutide or liraglutide significantly decreased waist circumference after 6 months.

    In plain wordsIn adults with type 2 diabetes, adding dulaglutide or liraglutide was linked to a smaller waist after 6 months.

    Peptide
    Liraglutide
    Outcome
    DecreaseWaist circumference change after 6 months
    Study

    n = 85

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    After 6 months of GLP-1 analogues a significant decrease in BMI (p < 0.001), waist circumference (WC) (p < 0.001), fasting blood glucose (p < 0.001), HbA1c (p < 0.001), total cholesterol (p < 0.001), LDL-cholesterol (p = 0.003), triglycerides (p = 0.017), IL-6 (p = 0.045) and a significant increase…
    1 context sentence
    Summary · context
    Eighty-five patients with T2DM inadequately controlled with insulin or other hypoglycaemic drugs were added to dulaglutide (N° = 44) and liraglutide (N° = 41) treatment.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes, pooled dulaglutide or liraglutide significantly decreased fasting blood glucose after 6 months.

    In plain wordsIn adults with type 2 diabetes, adding dulaglutide or liraglutide was linked to lower fasting blood sugar after 6 months.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting blood glucose change after 6 months
    Study

    n = 85

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    After 6 months of GLP-1 analogues a significant decrease in BMI (p < 0.001), waist circumference (WC) (p < 0.001), fasting blood glucose (p < 0.001), HbA1c (p < 0.001), total cholesterol (p < 0.001), LDL-cholesterol (p = 0.003), triglycerides (p = 0.017), IL-6 (p = 0.045) and a significant increase…
    1 context sentence
    Summary · context
    Eighty-five patients with T2DM inadequately controlled with insulin or other hypoglycaemic drugs were added to dulaglutide (N° = 44) and liraglutide (N° = 41) treatment.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes, pooled dulaglutide or liraglutide significantly decreased HbA1c after 6 months.

    In plain wordsIn adults with type 2 diabetes, adding dulaglutide or liraglutide was linked to lower HbA1c after 6 months.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change after 6 months
    Study

    n = 85

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    After 6 months of GLP-1 analogues a significant decrease in BMI (p < 0.001), waist circumference (WC) (p < 0.001), fasting blood glucose (p < 0.001), HbA1c (p < 0.001), total cholesterol (p < 0.001), LDL-cholesterol (p = 0.003), triglycerides (p = 0.017), IL-6 (p = 0.045) and a significant increase…
    1 context sentence
    Summary · context
    Eighty-five patients with T2DM inadequately controlled with insulin or other hypoglycaemic drugs were added to dulaglutide (N° = 44) and liraglutide (N° = 41) treatment.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 05HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes, pooled dulaglutide or liraglutide significantly decreased total cholesterol after 6 months.

    In plain wordsIn adults with type 2 diabetes, adding dulaglutide or liraglutide was linked to lower total cholesterol after 6 months.

    Peptide
    Liraglutide
    Outcome
    DecreaseTotal cholesterol change after 6 months
    Study

    n = 85

    Comparator
    Baseline
    Outcome group
    Lipids · Cardiovascular

    Source sentences

    Summary
    After 6 months of GLP-1 analogues a significant decrease in BMI (p < 0.001), waist circumference (WC) (p < 0.001), fasting blood glucose (p < 0.001), HbA1c (p < 0.001), total cholesterol (p < 0.001), LDL-cholesterol (p = 0.003), triglycerides (p = 0.017), IL-6 (p = 0.045) and a significant increase…
    1 context sentence
    Summary · context
    Eighty-five patients with T2DM inadequately controlled with insulin or other hypoglycaemic drugs were added to dulaglutide (N° = 44) and liraglutide (N° = 41) treatment.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 06HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes, pooled dulaglutide or liraglutide significantly decreased LDL-cholesterol after 6 months.

    In plain wordsIn adults with type 2 diabetes, adding dulaglutide or liraglutide was linked to lower LDL cholesterol after 6 months.

    Peptide
    Liraglutide
    Outcome
    DecreaseLDL-cholesterol change after 6 months
    Study

    n = 85

    Comparator
    Baseline
    Outcome group
    Lipids · Cardiovascular

    Source sentences

    Summary
    After 6 months of GLP-1 analogues a significant decrease in BMI (p < 0.001), waist circumference (WC) (p < 0.001), fasting blood glucose (p < 0.001), HbA1c (p < 0.001), total cholesterol (p < 0.001), LDL-cholesterol (p = 0.003), triglycerides (p = 0.017), IL-6 (p = 0.045) and a significant increase…
    1 context sentence
    Summary · context
    Eighty-five patients with T2DM inadequately controlled with insulin or other hypoglycaemic drugs were added to dulaglutide (N° = 44) and liraglutide (N° = 41) treatment.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  7. 07HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes, pooled dulaglutide or liraglutide significantly decreased triglycerides after 6 months.

    In plain wordsIn adults with type 2 diabetes, adding dulaglutide or liraglutide was linked to lower triglycerides after 6 months.

    Peptide
    Liraglutide
    Outcome
    DecreaseTriglycerides change after 6 months
    Study

    n = 85

    Comparator
    Baseline
    Outcome group
    Lipids · Cardiovascular

    Source sentences

    Summary
    After 6 months of GLP-1 analogues a significant decrease in BMI (p < 0.001), waist circumference (WC) (p < 0.001), fasting blood glucose (p < 0.001), HbA1c (p < 0.001), total cholesterol (p < 0.001), LDL-cholesterol (p = 0.003), triglycerides (p = 0.017), IL-6 (p = 0.045) and a significant increase…
    1 context sentence
    Summary · context
    Eighty-five patients with T2DM inadequately controlled with insulin or other hypoglycaemic drugs were added to dulaglutide (N° = 44) and liraglutide (N° = 41) treatment.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  8. 08HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes, pooled dulaglutide or liraglutide significantly decreased serum IL-6 after 6 months.

    In plain wordsIn adults with type 2 diabetes, adding dulaglutide or liraglutide was linked to lower IL-6, an inflammation marker, after 6 months.

    Peptide
    Liraglutide
    Outcome
    DecreaseSerum IL-6 change after 6 months
    Study

    n = 85

    Comparator
    Baseline
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    After 6 months of GLP-1 analogues a significant decrease in BMI (p < 0.001), waist circumference (WC) (p < 0.001), fasting blood glucose (p < 0.001), HbA1c (p < 0.001), total cholesterol (p < 0.001), LDL-cholesterol (p = 0.003), triglycerides (p = 0.017), IL-6 (p = 0.045) and a significant increase…
    1 context sentence
    Summary · context
    Eighty-five patients with T2DM inadequately controlled with insulin or other hypoglycaemic drugs were added to dulaglutide (N° = 44) and liraglutide (N° = 41) treatment.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  9. 09HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes, pooled dulaglutide or liraglutide significantly increased serum irisin after 6 months.

    In plain wordsIn adults with type 2 diabetes, adding dulaglutide or liraglutide was linked to higher irisin, a muscle hormone, after 6 months.

    Peptide
    Liraglutide
    Outcome
    IncreaseSerum irisin change after 6 months
    Study

    n = 85

    Comparator
    Baseline
    Outcome group
    Inflammation markers · Metabolic and weight

    Source sentences

    Summary
    After 6 months of GLP-1 analogues a significant decrease in BMI (p < 0.001), waist circumference (WC) (p < 0.001), fasting blood glucose (p < 0.001), HbA1c (p < 0.001), total cholesterol (p < 0.001), LDL-cholesterol (p = 0.003), triglycerides (p = 0.017), IL-6 (p = 0.045) and a significant increase…
    1 context sentence
    Summary · context
    Eighty-five patients with T2DM inadequately controlled with insulin or other hypoglycaemic drugs were added to dulaglutide (N° = 44) and liraglutide (N° = 41) treatment.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  10. 10HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes, after 12 months of pooled dulaglutide or liraglutide, levels did not differ significantly from those at 6 months.

    In plain wordsIn adults with type 2 diabetes, levels after 12 months of dulaglutide or liraglutide were not clearly different from levels at 6 months.

    Peptide
    Liraglutide
    Outcome
    No significant changeIrisin and IL-6 change from 6 to 12 months
    Study

    n = 85

    Comparator
    6-month levels
    Outcome group
    Inflammation markers · Metabolic and weight

    Source sentences

    Summary
    After 12 months of treatment no significant differences were found compared to the levels at 6 months.
    1 context sentence
    Summary · context
    Eighty-five patients with T2DM inadequately controlled with insulin or other hypoglycaemic drugs were added to dulaglutide (N° = 44) and liraglutide (N° = 41) treatment.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  11. 11HumanNot a test of Liraglutide aloneObservational studyMechanism

    In adults with type 2 diabetes on pooled dulaglutide or liraglutide, the change in irisin was significantly correlated with the change in total cholesterol (r = -0.293).

    In plain wordsIn adults with type 2 diabetes on dulaglutide or liraglutide, a larger rise in irisin was linked to a larger fall in total cholesterol.

    Peptide
    Liraglutide
    Outcome
    Not applicableCorrelation of change in irisin with change in total cholesterol
    Study

    n = 85

    Outcome group
    Lipids · Metabolic and weight

    Measurements

    Correlation r
    −0.293
    change in irisin vs change in total cholesterol

    Source sentences

    Summary
    The change in irisin from baseline (Δ_irisin) was significantly related to the changes in total-cholesterol (Δ_total-cholesterol) (r = -0.293; p = 0.020)
    1 context sentence
    Summary · context
    Eighty-five patients with T2DM inadequately controlled with insulin or other hypoglycaemic drugs were added to dulaglutide (N° = 44) and liraglutide (N° = 41) treatment.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  12. 12HumanNot a test of Liraglutide aloneObservational studyMechanism

    In adults with type 2 diabetes on pooled dulaglutide or liraglutide, the change in IL-6 was significantly correlated with the change in waist circumference (r = 0.347).

    In plain wordsIn adults with type 2 diabetes on dulaglutide or liraglutide, a larger fall in IL-6 was linked to a larger fall in waist size.

    Peptide
    Liraglutide
    Outcome
    Not applicableCorrelation of change in IL-6 with change in waist circumference
    Study

    n = 85

    Outcome group
    Inflammation markers · Metabolic and weight

    Measurements

    Correlation r
    0.347
    change in IL-6 vs change in waist circumference

    Source sentences

    Summary
    while the change in IL-6 (Δ_IL-6) was significantly related to the changes in WC (Δ_WC) (r = 0.347; p = 0.006).
    1 context sentence
    Summary · context
    Eighty-five patients with T2DM inadequately controlled with insulin or other hypoglycaemic drugs were added to dulaglutide (N° = 44) and liraglutide (N° = 41) treatment.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.